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Abstract
Synthetic peptides with sequences identical to fragments of the constant region of different classes (IgG, IgM, IgA) of
antibodies (Fc-peptides) exerted a fungicidal activity in vitro against pathogenic yeasts, such as Candida albicans, Candida
glabrata, Cryptococcus neoformans, and Malassezia furfur, including caspofungin and triazole resistant strains. Alanine-
substituted derivatives of fungicidal Fc-peptides, tested to evaluate the critical role of each residue, displayed unaltered,
increased or decreased candidacidal activity in vitro. An Fc-peptide, included in all human IgGs, displayed a therapeutic
effect against experimental mucosal and systemic candidiasis in mouse models. It is intriguing to hypothesize that some Fc-
peptides may influence the antifungal immune response and constitute the basis for devising new antifungal agents.
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Introduction
In their basic monomeric structure, antibodies (Abs) or
immunoglobulins (Igs) comprise two identical heavy (H) and light
(L) chains linked by disulfide bonds [1]. H and L chains contain a
variable region with three hypervariable domains (H1, H2, H3
and L1, L2, L3) defined complementarity determining regions
(CDRs). CDRs form the two antigen (Ag) binding sites of an Ab
and define its specificity while the constant part (Fc) triggers
different effector mechanisms through interaction with specific Fc
receptors on immune cells, and other immune molecules, such as
complement proteins. Five classes of Igs can be distinguished
according to the relative diversity of their H chains Fc (IgG, IgM,
IgA, IgE and IgD).
In previous studies we demonstrated that the CDRs, or related
peptidic fragments, from a recombinant single chain antiidiotypic
Ab (KT-scFv), may exert a fungicidal effect in vitro against Candida
albicans [2]. KT-scFv represented the internal image of a Pichia
anomala killer toxin (KT) characterized by the wide spectrum of
antifungal activity against yeasts and molds expressing specific cell
wall receptors, mainly constituted by b-glucans. A decapeptide,
designated as killer peptide (KP), derived by alanine substitution
from a fragment comprising part of KT-scFv CDR L1 (P6), proved
to be active, in vitro, against different pathogenic fungi and to exert
effective therapeutic activity in experimental models of vaginal and
systemic candidiasis, disseminated cryptococcosis and paracoccid-
ioidomycosis [3]. KP, which proved to be devoid of cytotoxicity on
human PBMCs and mammalian cells, is characterized by a peculiar
self-aggregation-releasing property, catalyzed by b 1,3-glucan,
which might be at the basis of its unexpected pharmacokinetic
characteristics [4].
According to the frequent inclusion of P6 within the sequences
of the V regions of many Abs, as can be seen in available
databases, it was hypothesized that isolated CDRs may display
antifungal activities irrespective of Ab specificity for a given Ag [5].
CDR-based synthetic peptides of murine and human monoclonal
(m)Abs, characterized by unrelated specificities, showed fungicidal
activities in vitro and/or in vivo against various fungi, conceivably
involving different mechanisms of action. Engineered peptides,
obtained by alanine substitutions of CDR sequences, showed
increased, unaltered or decreased antifungal activities [5]. The
finding suggests that Abs may be sources of an unlimited number
of sequences potentially active against pathogenic fungi [3].
Although of interest, the potential antifungal activity of Ab CDRs
may be considered of relative importance from an immunological
point of view, since it is unlikely that a significant amount of the
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selectionandsynthesisofpeptidesencompassingsequencesoftheFc
(Fc-peptides) from the major classes of Igs (IgG, IgM, IgA), and the
evaluation of their antifungal activity. Fc-peptides with fungicidal
activity, that might be released in vivo by proteolysis of Igs, may
represent a link between adaptive and innate immunity playing a
role against fungal infections. Such peptides, moreover, could
constitute novel lead molecules for devising new antifungal agents.
Materials and Methods
Ethics statement
Procedures involving animals and their care were conducted in
conformity with national and international laws and policies. The
study has been approved by the Committees on the Ethics of
Animal Experiments of the University of Perugia (Permit Number:
41-2005B and 34/2003-A) and Istituto Superiore di Sanita `, Rome
(Permit Number: DM 227/2009-B dated 12/21/2009).
Selection and synthesis of Fc-peptides and their
derivatives
Abs sequences were found in the Protein Information Resource
(PIR) database (http://pir.georgetown.edu/). The selection of Fc-
peptides was made by using the following analysis tools: BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi); ClustalW (http://www.
ebi.ac.uk/Tools/msa/clustalw2/); ExPASy Proteomics Tools
(http://expasy.org/tools/); The Sequence Manipulation Suite 2
(http://www.bioinformatics.org/sms2/index.html). The definition
of Fc-peptides of interest within each Ig class (IgG, IgM and IgA)
was made according to different criteria: peptide length (maximum
12 amino acids), potential cleavage sites by trypsin and/or
chymotrypsin-high specificity proteases, cleavage probability of
the individual sites, conserved amino acids in human Ig and in
different organisms, isoelectric point, and alternation of hydro-
phobic/hydrophilic residues in the sequence. Selected Fc-peptides
(Table 1, Fig. 1) were synthesized, to be used for the studies of in
vitro fungicidal and in vivo therapeutic antifungal activity, using
Fmoc solid-phase synthesis chemistry on a Syro II Peptide
Synthesizer (MultiSynTech, Germany) at CRIBI (Biotechnology
Centre, University of Padova, Italy).
An irrelevant synthetic decapeptide (MSTAVSKCAT), previ-
ously proven to be devoid of fungicidal activity [2], was
synthesized to be used in some experiments as a negative control.
Selected Fc-peptides proven to exert fungicidal activity in vitro
were analysed by alanine-scanning. Alanine-substituted derivatives
(asds), defined according to the position held by the alanine-
substituted amino acid, were tested in selected experiments to
critically establish the functional relevance of each residue.
Fungal strains
The following fungal strains were employed for the evaluation
of the fungicidal activity of selected Fc-peptides: C. albicans SC5314
a well known reference laboratory strain; C. albicans CA-6, a highly
virulent strain whose origin and characteristics have previously
been described [6] (from the fungal collection of the Microbiology
Section, Department of Experimental Medicine and Biochemical
Sciences, University of Perugia, Italy); C. albicans SA40 and
AIDS68, fluconazole susceptible and resistant strains, respectively,
originally isolated from a human vaginal infection (from the fungal
collection of the Department of Infectious, Parasitic and Immuno-
mediated Diseases, Istituto Superiore di Sanita `, Rome, Italy); C.
albicans UM4, caspofungin resistant, and Candida glabrata OMNI32,
fluconazole, itraconazole, and voriconazole resistant (from the
fungal collection of the Department of Public Health, University of
Milan, Italy); C. neoformans var. neoformans 6995, a capsulated
serotype A strain (University of Perugia), and Malassezia furfur 101
(a clinical isolate from the collection of the University of Parma). C.
albicans 64548 from the American Type Culture Collection was
used in transmission electron and confocal microscopy studies.
Evaluation of the in vitro fungicidal activity of selected
Fc-peptides
Selected Fc-peptides, or their asds, were preliminarily tested at
the concentration of 100 mg/ml. Peptides exhibiting fungicidal
activityat this concentrationwere furthertestedatscalardilutionsto
determine the half maximal effective concentration (EC50) values.
Conventional colony forming unit (CFU) assays were performed as
previously described [2]. Briefly, yeast cells from a fresh (20 h at
30uC) actively growing colony on Sabouraud Dextrose agar (SDA)
(C. albicans, C. glabrata, C. neoformans) or on SDA supplemented with
1% Tween 20 (M. furfur) were suspended in 199 medium. Initial
germination was induced in C. albicans cells by incubation for 1 h at
37uC with shaking. Suspensions were properly diluted to obtain
approximately 500 fungal cells in 100 ml of distilled water in the
presence or absence (control growth) of the synthetic Fc-peptide to
be tested. Cell suspensions were incubated at 37uC for 6 h, then
plated on SDA or SDA-Tween. CFU were enumerated after 48–
72 h of incubation at 30uC, and peptide fungicidal activity was
determined as percentage of CFU inhibition, according to the
formula 100-(CFU Fc-peptide treated/CFU control growth)6100.
Each assay was carried out in triplicate for statistical purposes. In
preliminary experiments, the decapeptide MSTAVSKCAT was
used as additional control.
EC50 was calculated by nonlinear regression analysis using
Graph Pad Prism 4.01 software, San Diego, CA, USA.
Table 1. Characteristics of peptides selected from the constant region of antibodies.
Peptide Amino acid sequence Ig class
Proteases involved
in cleavage %
a Hydrophobicity
b pI M.M. (Da) Net charge
H4L HEAL IgG, IgM, IgA
c -- +-00 5.12 468.49 2
N10K NQVSLTCLVK IgG1
c Tryp+Tryp 81,4 **0*0**00+ 8.23 1104.33 +
T11F TCRVDHRGLTF IgM
d Chym+Chym 63,5 **+0-++00*0 8.27 1304.51 +
acleavage probability;
b0: hydrophobic, *: polar, +,a n d2: positively charged and negatively charged residues;
cconserved amino acids in human Ig and different organisms;
dconserved amino acids only in human Ig;
pI, isoelectric point; M.M., molecular mass (dalton); Tryp, trypsin; Chym, chymotrypsin.
doi:10.1371/journal.pone.0034105.t001
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effects of selected peptides (H4L, N10K and its asd N1A,
T11F and its asd D5A)
Selected FC-peptides and asds were tested for their hemolytic
activities against human red blood cells (group 0 Rh+) (hRBC).
Freshly collected hRBC with EDTA were rinsed 3 times with
phosphate buffered saline (PBS) by centrifugation for 10 min at
1300 g and resuspended in PBS. Serial dilutions of Fc-peptides in
PBS were then prepared and added to 150 ml of the stock hRBC
solution to a final concentration of 500, 250, 100 and 50 mg/ml in
the volume of 300 ml (final erythrocyte concentration, 2.5% v/v).
The resulting suspensions were incubated with shaking for 30 min
and 2 h at 37uC. 100 ml of the samples were then centrifuged at
800 g for 10 min. Release of hemoglobin was monitored by
measuring the absorbance of the supernatant at 540 nm. Controls
for zero hemolysis (blank) and 100% hemolysis consisted of hRBC
suspended in PBS and Triton 1%, respectively.
Cytotoxicity against LLC-MK2 monkey kidney epithelial cells
was determined by MTT assay, based on the ability of
metabolically active cells to convert the yellow water-soluble
tetrazolium salt into formazan crystals. LLC-MK2 cells cultured in
MEM containing 10% fetal bovine serum (FBS) were seeded in
96-well plates (1610
5 cells/ml, 100 ml/well) and incubated for
24 h at 37uCi n5 %C O 2 atmosphere. The cells were then treated
with the selected peptides in medium containing 2% FBS (final
concentrations 50, 100, 250 e 500 mg/ml) for 24 h. Cells in
medium without peptides served as control. After this period, cells
were incubated with MTT (5 mg/ml, 10 ml/well) in serum-free
medium for 2 h at 37uC, the medium was removed and the crystal
formazan dye was solubilized by adding 100 ml isopropanol (with
5% HCl 1 M). Absorbance was measured at 540 nm.
To detect if selected Fc-peptides might induce DNA damage,
Alkaline Comet assay was performed on PBMCs. PBMCs were
obtained from healthy donor whole blood by Lymphoprep
TM
density gradient and, after two washes in HBSS, cultured at a
concentration of 1610
6 cells/ml in RPMI 1640 containing 10%
FBS, 1% phytohemoagglutinin, 1 mM L-glutamine, 100 IU
penicillin, and 100 mg/ml streptomycin. PBMCs were treated for
2 h with different concentrations of the selected peptides (5 mM,
10 mM, 20 mM) at 37uCi n5 %C O 2 atmosphere. The Comet
assay was performed as described by Singh et al. [7], with minor
modifications. Cell lysis was carried out at 4uC overnight by
exposing the cells to a buffer containing 2.5 M NaCl, 10 mM
Na2EDTA, 10 mM Tris-HCl, 1% Triton X-100 and 10%
DMSO, pH 10. DNA unwinding was achieved over 20 min in
an electrophoretic alkaline buffer (1 mM Na2EDTA, 300 mM
NaOH, 0uC, pH.13), electrophoresis was then carried out for
20 min, (0.78 V/cm, 300 mA) at 0uC in the same buffer, followed
by neutralisation in 0.4 M Tris-HCl, pH 7.5. Immediately before
microscopic examination, the slides were stained with 0.75 ml
ethidium bromide (10 mg/ml). The slides were examined with a
fluorescent microscope (Leica DMLS), equipped with a BP 515–
560 nm excitation filter and an LP 580 nm barrier filter, and data
Figure 1. Localization of the selected peptides within the constant region of different antibody isotypes.
doi:10.1371/journal.pone.0034105.g001
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Assay III, Perceptive Instruments Ltd). Fifty randomly-selected
cells per slide (two slides per sample) were analyzed. The samples
were coded and evaluated blind. DNA migration was evaluated by
percentage of DNA in comet tail (Tail Intensity, expressed as
mean of the median values).
Evaluation of the therapeutic activity of a selected Fc-
peptide
Experimental systemic infection. Female Balb/c mice
(Harlan Nossan Laboratories), 8–10 weeks old, were housed at
the Animal Facilities of the University of Perugia, Perugia, Italy.
Groups of 8 animals were infected intravenously with 5610
5 or
7.5610
5 C. albicans CA-6 cells suspended in 0.5 ml saline solution,
for evaluation of fungal clearance or mice survival, respectively.
Infected animals were given 200 mg of N10K peptide
intraperitoneally 1, 24, and 48 h after infection for a total dose
of 600 mg/mouse. Infected animals treated with the same amount
of the negative control peptide or untreated (i.e. injected with the
peptide solvent) served as controls. Quantification of fungal renal
burden at 7 and 12 days after infection was assessed by plating
serial dilutions of kidney homogenates onto SDA plates. Animal
survival was monitored up to 60 days after infection.
Experimental vaginal infection. Female Balb/c mice (18–
21 g) (Charles River) were housed at the Animal Facilities of the
Istituto Superiore di Sanita `, Rome, Italy. Groups of 5 animals
were injected subcutaneously with 0.02 mg of estradiol benzoate
(Amsa Farmaceutici srl, Rome, Italy) in 100 ml of saline solution,
48 h before inoculation with Candida and weekly thereafter. The
animals were inoculated intravaginally with 20 ml of saline solution
containing 10
6 cells of C. albicans SA40 or AIDS68 strains. The
inoculum was dispensed into the vaginal cavity through a syringe
equipped with a multipurpose calibrated tip (Combitip; PBI,
Milan, Italy). The yeast cells were previously grown in YPD broth
(1% yeast extract, 2% peptone, 2% dextrose) at 28uC on a rotatory
shaker (200 rpm), harvested by centrifugation (1500 g), washed,
counted in a hemocytometer, and suspended to the required
number in saline solution. N10K was administered intravaginally
three times at 1, 24, and 48 h after intravaginal C. albicans
challenge (20 mg per dose in 20 ml of distilled water) for a total of
60 mg/mouse. Infected animals treated with the same amount of
the negative control peptide or untreated served as controls. As a
further control, in selected experiments mice received 100 mgo f
fluconazole (Pfizer) in PBS (20 ml) at 1, 24, and 48 h after the yeast
challenge. The number of cells in the vaginal fluid was counted by
culturing 100 ml of vaginal samples, taken by washing the vaginal
cavity by gentle aspiration of 100 ml of sterile saline solution,
repeated four times, at 1:10 serial dilutions on SDA containing
chloramphenicol (50 mg/ml). CFUs were enumerated after
incubation at 28uC for 48 h. The outcome of treatment was
assessed in terms of acceleration of fungal CFU clearance over a
period of 28 days.
Statistical analysis
Data are reported as the mean 6 sd. Statistical significance of
survival curve of animals was assessed by the Kaplan-Meier
logrank test. Statistical significance of vaginal fungal clearance was
assessed by the analysis of variance (ANOVA) and the Bonferroni
post hoc test. A value of P,0.05 was considered significant.
Circular Dichroism (CD) spectroscopy
CD measurements were carried out on a Jasco 715 Spectro-
polarimeter (JASCO International Co. Ltd.) coupled to a Peltier
PTC-348WI system for temperature control. N10K stock solution
was 1.8 mM and, to follow the aggregation process, aliquots were
diluted to a final concentration of 100 mM. Far-UV spectra were
recorded in the spectral range 190–250 nm and averaged over
four scans, using a 1 mm path length quartz cell, at 20uC.
Following baseline correction, the measured ellipticity, h (mde-
gree), was converted to the molar mean residue ellipticity [h]
(deg?cm
2?dmol
21). The spectra of N10K (1 mM) in the presence
of C. albicans (5610
7 cells/ml) were collected at 20uC using a
0.1 mm path length cell.
Transmission electron microscopy studies
For the electron microscopy studies, aliquots of peptide solution
(N10K and negative control peptide) were applied to Formvar-
coated grids, and negatively stained with a solution of 2% (w/v)
uranyl acetate in water. The grids were washed, air-dried, and
then examined in a Philips EM 208S transmission electron
microscope (Fei Europe, Eindhoven, The Netherlands) operating
at an accelerating voltage of 80 kV.
For transmission electron microscopy studies on yeasts, C.
albicans ATCC 64548 cells (approximately 10
7) were incubated in
the absence (control) or presence of N10K (150 mg) for 1 h.
Negative control peptide served as an additional control. Cells
were fixed with 2.5% glutaraldehyde in sodium cacodylate
[Na(CH3)2 AsO2 N 3H2O] buffer. After washing, 4 times, 15 min
each, with 100 mM cacodylate buffer, pH 7.4 at 4uC, the pellet
was post-fixed in the same buffer with 1% osmium tetroxide for
2 h. Dehydration was carried out by immersion in ethanol in a
70% to 100% gradient (twice for 10 min at 70%; twice for 10 min
at 95% and 4 times for 15 min at 100%). The pellet was then
incubated 2 times (15 min each) in 100% propylene oxide at room
temperature followed by a mixture of propylene oxide and Spurr
resin (v/v) at room temperature for 12 h. Materials were then kept
in pure resin for 5 h, at room temperature, and then in a new
solution of pure resin at 70uC for 72 h. Semi-thin cuts (300 nm)
were stained with 0.25% toluidine blue for observation in an
optical microscope (Axiophot Zeiss, with plan achromatic
objective), followed by ultra-thin cuts (70 nm) which were
contrasted with 0.5% uranyl acetate and 0.5% lead citrate and
observed in an EM Jeol 100 CX transmission electron microscope.
Confocal microscopy studies
C. albicans ATCC 64548 cells (2610
7) were incubated for 1 h at
room temperature with biotinylated N10K, washed 3 times with
PBS and fixed with 4% paraformaldehyde for 1 h. The cells were
permeabilized in 0.2% Triton X-100 for 1 h and blocked with
buffer (150 mM NaCl, 50 mM Tris and 0.25% BSA) for 1 h.
Permeabilized cells were then incubated for 1 h in the dark with
streptavidin-fluorescein isothiocyanate (Invitrogen, Camarillo, CA)
diluted 1:200 in PBS. Cells were then washed and stained with
phalloydin-rhodamine (1:1000) (Invitrogen) for 1 h, followed by
DAPI (1:3000) (Invitrogen) staining for 1 h. Cells were washed 3
times with PBS and 40 ml of VectashieldH mounting medium
(Sigma) was added to the pellet. A sample of 20 ml was mounted
on coverslips and observed in a Confocal Leica SP5 microscope,
with a 6361.4 oil objective; the Z series was obtained according
with sampling criteria built in the software. DAPI, which stains the
nucleus in blue, was examined at 350 nm excitation and 470 nm
emission, and the streptavidin-FITC at 494 nm excitation and
520 nm emission. For phalloidin-rhodamine that stains filamen-
tous actin in red, the excitation at 580 nm and emission at 604 nm
were used.
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Properties of selected Fc-peptides
The amino acid sequences and properties of the selected peptides
are shown in Table 1. Their localization within the constant region
of the different classes of Abs is shown in Figure 1. In particular,
H4L peptide was selected because it occurs in the C region of all
human and mammalian IgAs, IgGs, and IgMs. N10K, a fragment
of human IgG1 conserved in different organisms, and T11F, a
fragment of human IgMs, resulting from the digestion by trypsin
and chymotrypsin, respectively, were selected according to their
high isoelectric point, and the alternation of hydrophobic/
hydrophilic residues in the sequence, with regard to our previous
experience in the field of antifungal Ab peptides.
In vitro fungicidal activity of selected Fc-peptides
The in vitro fungicidal activity of the selected peptides was
assessed by CFU assays. N10K and T11F exhibited significant
activity against all the investigated fungal strains, while H4L
showed a weaker activity (Table 2). The negative control peptide,
recognized to be devoid of anti-Candida properties [2], proved, in
preliminary assays performed at the concentration of 100 mg/ml,
to have no fungicidal activity against the tested strains (data not
shown). EC50 values, determined for the two most active Fc-
peptides, ranged between 0.1 and 3.5 mM. In comparison to the
parental Fc-peptides N10K and T11F, their alanine substituted
derivatives were tested in the same biological assay against C.
albicans SC5314 in order to study the role of each residue in
antifungal activity. Results (Tables 3 and 4, respectively) showed a
candidacidal activity significantly increased or decreased, with the
only exception of T11F asd G8A whose EC50 value was
comparable to the one of the parental Fc-peptide.
Hemolytic, cytotoxic, and genotoxic effects of selected
Fc-peptides
The Fc-peptides N10K, its most active asd N1A, T11F, its most
active asd D5A, and H4L were tested for hemolytic, cytotoxic and
genotoxic effects on human red blood cells, mammalian cells and
human PBMCs.
All tested peptides showed no hemolytic activity at the
concentrations and time investigated, as demonstrated by the
statistical analysis of the mean absorbance values of released
hemoglobin that did not differ significantly from the ones of the
negative control (PBS, 0.0360.01 at 30 min, 0.0560.01 at 2 h) in
comparison to the positive control (Triton 1%, 1.5060.01 at
30 min, 1.5160.11 at 2 h).
None of the investigated peptides was significantly cytotoxic
against LLC-MK2 cells as assessed by the MTT assay. At all
concentrations tested, mean absorbance values were not different
from the ones of the untreated cells with the exception of N10K
and N1A asd peptides. In the latter two cases only at the
concentration of 500 mg/ml, respectively 450 and 800 times
higher than the EC50, cell viability was reduced ,10% in
comparison to untreated control.
None of the tested peptides showed genotoxic activity in the
Comet assay performed on PBMCs. No statistically significant
increases were observed in % tail DNA in comparison with the
negative control value of 0.2460.05 recorded for untreated
PBMC.
In vivo therapeutic activity of N10K
N10K was selected as a proof-of-concept of the therapeutic
potential of fungicidal Fc-peptides in consolidated models of
murine systemic and mucosal candidiasis.
Systemic candidiasis. Treatment with three doses (200 mg/
dose, i.e. 180 mM) of N10K led to a significant increase in survival
of mice infected with C. albicans CA-6 in comparison to infected
mice treated with the same amount of negative control peptide
(Figure 2, panel A). N10K treatment significantly reduced fungal
burden in the kidneys of infected mice (Figure 2, panel B). Results
in animal groups treated with saline were not statistically different
from the results obtained in mice treated with the negative control
peptide (data not shown).
Vaginal candidiasis. Administration of three doses (20 mg/
dose, i.e. 18 mM) of N10K accelerated the early rate of clearance
(1 to 5 days) of the fungus from the vagina of the mice infected
with either fluconazole-susceptible SA40 (Figure 3, panel A) or
fluconazole-resistant AIDS68 (Figure 3, panel B) C. albicans strains.
N10K also provided a substantial resolution of the infection
(approximately 2610
3 CFU/ml of vaginal fluid) within 3 weeks of
challenge, when the animals treated with the same amount of the
negative control peptide or untreated still had from 7.8610
3 to
Table 2. In vitro fungicidal activity of the selected Fc-peptides against fungal strains.
Fungicidal activity
N10K T11F H4L
Fungal strain %*
EC50**(95% confidence intervals)
[mol/liter]610
26 %
EC50 (95% confidence intervals)
[mol/liter]610
26 %E C 50
C. albicans SC5314 100 1.004 (0.947–1.065) 100 1.540 (1.404–1.689) 84.34 n.d.
C. albicans CA-6 100 2.939 (2.578–3.351) 100 0.518 (0.506–0.531) 57.04 n.d.
C. albicans SA40 100 1.763 (1.670–1.861) 100 0.286 (0.251–0.326) 55.99 n.d.
C. albicans AIDS68 100 1.745 (1.396–2.180) 100 0.295 (0.254–0.341) 59.82 n.d.
C. albicans UM4 100 2.784 (2.622–2.956) 100 0.667 (0.636–0.700) 64.63 n.d.
C. glabrata OMNI32 100 3.584 (3.390–3.788) 100 0.252 (0.245–0.260) 80.49 n.d.
C. neoformans 6995 100 2.948 (2.645–3.288) 100 0.811 (0.632–1.041) 85.08 n.d.
M. furfur 101 100 2.833 (1.900–4.226) 100 0.115 (0.103–0.129) 92.04 n.d.
*% inhibitory activity at 100 mg/ml in comparison to the control growth (water);
**EC50, half maximal effective concentration;
n.d., not determined.
doi:10.1371/journal.pone.0034105.t002
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4 Candida CFU/ml of vaginal fluid. No acceleration of the
fungal clearance and no effect on resolution of infection was
provided by administration of the negative control peptide.
Noteworthy, N10K proved to have a therapeutic effect also in
mouse vaginal infection caused by the C. albicans strain (AIDS68)
which was resistant to treatment with 100 mg of fluconazole
(Figure 3, panel B).
N10K conformational state
Studies on the structure-function relationship of N10K peptide
carried out by Circular Dichroism spectroscopy revealed its ability
to spontaneously aggregate. CD spectra of pure N10K in water
(Figure 4, panel A), recorded over time, illustrate the progression
of its aggregation, going from a typical random coil conformation
to a rich b-sheet structure. In 9 h the peptide reached its final
conformation. When N10K was in the presence of C. albicans, the
CD spectrum recorded at 150 min of incubation was indicative of
the onset of b-sheet elements as observed for the pure peptide in
water after a much longer incubation time (Figure 4, panel B).
Electron micrographs of the negatively stained N10K demon-
strated the presence of a network of fibril-like structures (Figure 4,
panel C), while, in the same conditions, negative control peptide
showed no aggregation (Figure 4, panel D).
Visualization of the effects of N10K on Candida albicans
cells by transmission electron microscopy
As shown in Figure 5, treatment with N10K caused gross
alterations in the morphology of C. albicans cells. Aggregates of
Table 4. In vitro comparative fungicidal activity of T11F alanine-substituted derivatives against Candida albicans SC5314.
Anti-Candida activity
asd
1 M.M. (Da) %* EC50**(95% confidence intervals) [mol/liter]610
26 EC50asd/EC50 T11F
T1A 1274.45 100 0.738 (0.711–0.766)
1 0.48
C2A 1272.41 79.32 32.521 (25.220–41.944)
1 21.12
R3A 1219.37 97.61 13.458 (12.146–14.909)
1 8.74
V4A 1276.42 100 1.134 (1.083–1.188)
1 0.74
D5A 1260.47 100 0.395 (0.389–0.402)
1 0.26
H6A 1238.41 100 10.417 (9.948–10.901)
1 6.76
R7A 1219.37 100 12.055 (11.498–12.646)
1 7.83
G8A 1318.50 100 1.551 (1.465–1.642) 1.01
L9A 1262.39 100 1.753 (1.679–1.830)
1 1.14
T10A 1274.45 100 0.850 (0.844–0.854)
1 0.55
F11A 1228.38 100 2.519 (2.433–2.607)
1 1.64
1asd, alanine-substituted derivative; M.M., molecular mass (dalton);
*% inhibitory activity at 100 mg/ml in comparison to the control growth (water);
**EC50, half maximal effective concentration.
1Anti-Candida activity significantly different from that of T11F peptide as assessed by t test (P,0.001, except in the case of L9A, P=0.0098).
doi:10.1371/journal.pone.0034105.t004
Table 3. In vitro comparative fungicidal activity of N10K alanine-substituted derivatives against Candida albicans SC5314.
Anti-Candida activity
asd
1 M.M. (Da) %* EC50**(95% confidence intervals) [mol/liter]610
26 EC50asd/EC50 N10K
N1A 1061.30 100 0.587 (0.586–0.588)
1 0.58
Q2A 1047.28 100 2.305 (2.260–2.350)
1 2.30
V3A 1076.28 100 5.929 (5.064–6.941)
1 5.91
S4A 1088.33 100 2.391 (2.076–2.755)
1 2.38
L5A 1062.25 100 0.885 (0.841–0.931)
1 0.88
T6A 1074.30 100 4.878 (4.364–5.453)
1 4.86
C7A 1072.27 73.41 54.874 (26.243–114.710)
1 54.66
L8A 1062.25 100 0.744 (0.732–0.755)
1 0.74
V9A 1076.28 100 1.776 (1.742–1.810)
1 1.77
K10A 1047.23 0 n.d. n.d.
1asd, alanine-substituted derivative; M.M., molecular mass (dalton);
*% inhibitory activity at 100 mg/ml in comparison to the control growth (water);
**EC50, half maximal effective concentration;
1Anti-Candida activity significantly different from that of N10K peptide as assessed by t test (P,0.001).
n.d., not determined.
doi:10.1371/journal.pone.0034105.t003
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organelles engulfed in single or double compartments were seen
(panels B, C, D). Panels E, F, and G show yeast cells with extensive
disruption of internal structures. In all cases N10K formed
aggregates binding to the cell wall without causing major cell lysis.
Treatment with negative control peptide did not affect Candida
cells (not shown).
Binding of biotinylated N10K to Candida albicans cells
Biotin-labeled N10K peptide was used in order to evaluate
binding to C. albicans cells. N10K bound to the surface of Candida
cells, apparently to a cell wall ligand. Confocal fluorescence
microscopy showed that the peptide does not colocalize with
phalloidin-rhodamine, a reagent that is quite specific for
filamentous actin (Figure 6).
Discussion
Fungal infections remain a major threat in humans because of
the emergence of multidrug resistant strains [8,9,10]. Peptide
molecules of innate immunity (host defence peptides, HDPs, such
as defensins, histatins, etc.) have been recognized to display
antifungal activity mainly owing to interactions with cell
membranes or inhibition of metabolism [11,12,13,14].
We had shown that, irrespective of the specificity of the native
Ab for a given Ag, CDR-related peptides may exert differential in
vitro, ex vivo and/or in vivo antimicrobial, antiviral, antitumor and/
or immunomodulatory activities, conceivably mediated by differ-
ent mechanisms of action, reminiscent of molecules of innate
immunity [2,5,15,16].
In this work, Fc-peptides putatively arising from the cleavage of
the constant region of Abs (IgG, IgM, IgA) by physiological
enzymes (trypsins, chimotrypsins) proved to display in vitro
antifungal activity against fungal pathogens, such as C. albicans,
C. glabrata, C. neoformans, and M. furfur. N10K and T11F asds, used
Figure 2. In vivo anti-Candida activity of N10K in a systemic
model of infection. A. Effect of N10K treatment (200 mg, i.e. 180 mM,
1, 24, and 48 h postchallenge) on the survival of mice infected
intravenously with 7.5610
5 cells of C. albicans CA-6. The survival curve
of N10K-treated animals was significantly different from that of control
mice, treated with an irrelevant peptide (negative control, NC), as
assessed by Logrank test (P,0.05). B. Effect of N10K treatment on
fungal clearance from kidneys of mice challenged with 5610
5 cells of C.
albicans CA-6. *, P,0.01 N10K-treated vs mice treated with the negative
control peptide (NC).
doi:10.1371/journal.pone.0034105.g002 Figure 3. Protection conferred by N10K upon mice intravag-
inally infected with fluconazole-susceptible strain SA40 (panel
A) and fluconazole-resistant strain AIDS68 (panel B) of C.
albicans. All mice (five per group) were given 10
6 cells in 20 ml of saline
solution on day 0 and were sampled for initial intravaginal colony
forming units (CFU). The therapeutics (N10K, 20 mg, i.e. 18 mM; negative
control peptide, NC, 20 mg; and fluconazole, Flu,100 mg) were
administered 1, 24, and 48 h postchallenge. On days 1, 2, 5, 7, 14,
and 21, all the differences in the CFU vaginal counts between N10K-
treated and control groups (untreated and NC-treated) were statistically
significant (P,0.001). The differences in vaginal CFU counts between
N10K-treated and fluconazole-treated AIDS68-infected animals were
statistically significant (P,0.001 all days except P,0.01 day 14) on the
same days. The statistical significance was assessed by the analysis of
variance (ANOVA) and the Bonferroni post hoc test. Data are from one
of two experiments performed with similar results.
doi:10.1371/journal.pone.0034105.g003
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showed increased, unaltered or decreased candidacidal activity in
comparison to parental peptides. Replacement of cysteine in both
N10K and T11F, that hampers disulphide bond formation,
determined the most significant reduction of candidacidal activity,
followed by substitution of positively charged residues (lysine in
N10K, histidine and arginine in T11F). In the case of N10K, the
substitution of the unique positively charged residue that makes
the peptide highly hydrophobic (with net charge 0), lowered its
solubility. The substitution of a single positively charged residue of
T11F (the histidine or one of the arginines), caused a comparable
reduction of candidacidal activity. In contrast, the replacement of
the only negatively charged residue, aspartic acid, caused a
significant increase in candidacidal activity. These findings
emphasize the role of the positive net charge of T11F in the
interaction with the yeast. Overall, the results are in agreement
with the accepted notion that a net positive charge is critical to
sustain the activity of antimicrobial peptides [11,12].
Noteworthy, Fc-peptides did not show hemolytic, cytotoxic or
genotoxic activity, as could be expected from peptide fragments
potentially occurring in the bloodstream.
Significantly, the selected Fc-peptide N10K, when administered
in mouse models of systemic and vaginal candidiasis, displayed a
therapeutic activity. In particular, N10K treatment allowed long-
term survival of almost half of the mice systemically infected with
C. albicans in an infection model in which all control animals died
within five days post-challenge. Differences in the CFU recovery
from the kidneys of treated and control mice strengthened this
observation. Equally, N10K treatment proved to significantly
accelerate the clearance from the vagina of a high fungal burden in
a consolidated experimental model of mouse mucosal candidiasis.
N10K greatly accelerated the yeast elimination from mouse vagina
in the first 2 to 3 days of infection, a critical period when the
infecting yeast cells undergo massive germination to form hyphae
and secrete critical virulence enzymes, such as the aspartyl
proteinases, thus resulting in aggressive invasion and damage of
Figure 4. Characterization of N10K conformational transition. A. Far-UV CD spectra of N10K (100 mM) in water, recorded as a function of
time: time 0 (
______); 1 h (— — ); 3 h (- - -); 5 h (— - — -); 7 h (— - - — - -); 20 h (– – –); 6 days (NNN ); 20 days (—N —N). B. Interaction of N10K
(1 mM) with C. albicans (5610
7 cell/ml) after 150 min incubation (
______) using a 0.1 mm path lenght cell, 20uC. Fresh N10K in water (— —); after
150 min incubation (— - — -); after 570 min incubation (- - -). The samples in water were prepared taking aliquots of 100 mM from a 1.8 mM stock
water solution and were collected with a 1 mm cell. For the sake of comparison of these CD profiles with the one obtained in the presence of C.
albicans, the signal intensity of the water CD spectra has been divided by 10 and the ordinate kept in h (mdeg). C. Electron micrograph of N10K
prepared diluting 1:5 the stock water solution stored at 4uC for 20 days. D. Electron micrograph of negative control peptide prepared in the same
conditions.
doi:10.1371/journal.pone.0034105.g004
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the infection caused by a fluconazole-resistant C. albicans strain, a
finding of special interest in view of the clinical concern about
increasing antifungal resistance [8].
We hypothesize that the therapeutic activity of N10K in the in
vivo assays could be due to its aggregation ability and,
consequently, prolonged life-time. Resistance to protease-induced
degradation has been observed for the KP peptide, as previously
described [4]. In fact, also in this case the alternation of
hydrophobic/hydrophilic residues favours the acquisition of a b-
sheet structure and the formation of large aggregates. In addition,
the presence of more hydrophobic residues, when compared to the
KP peptide, explains the faster aggregation process, i.e. days for
KP and only hours for N10K.
Electron microscopy observation of N10K-treated C. albicans
cells may suggest that the peptide does not directly lyse the cells
but causes lethal effects seen as cytoplasm retraction and masses of
disrupted materials within compartments resembling autophagic
structures. Since the cell wall remained intact with many peptide
aggregates bound to it, apparently a cytotoxic signal is triggered to
induce hydrolytic enzymes that act inside the cell.
These findings may vanish the traditional distinction between
adaptive and innate immunity and lead to the hypothesis that,
during evolution, the immune system may have adopted an
unpredictable range of solutions for host defence against fungal
infections. It is now well known that a wide range of proteins
contain concealed functional units, that can be released by
proteolytic cleavage, with biological activities that cannot be
predicted from either the amino acid sequence or the activity of
the parent, precursor protein. These ‘‘hidden’’ or ‘‘cryptic’’
peptides were called ‘‘cryptides’’. They might increase the array
of biological roles that can be associated to one given protein and
potentially offer new opportunities for peptide-based therapeutics
[18,19,20,21]. Cryptides have been divided into three types:
peptides detected in vivo with functions entirely different from (type
I) or related but not necessarily identical to (type II) those of their
precursors, and peptides produced in vitro by proteolytic digestion
of proteins that may or may not exist in vivo (type III) [18]. The Fc-
peptides described in this paper, which are characterized by
antifungal activity, belong to type III, as they were derived from
the amino acid sequence analysis of the different classes of Abs by
bioinformatic approaches. The demonstration of the presence of
Fc-peptides released in vivo from antibodies, and of the role played
in the antifungal response by these molecules, would be important.
Mass spectrometry-based approaches [22] could be extensively
used to qualitatively and quantitatively search for these and other
Fc-cryptides in human sera from individuals in various clinical
conditions. As a matter of fact, Abs could be added to the list of
proteins from which cryptides can be derived, so far limited to
proteins associated with endocrine signalling, extracellular matrix,
complement cascade and milk [20,21].
Overall, our findings show that synthetic Fc-peptides may,
likewise Fab-peptides, exert in vitro and in vivo fungicidal activities.
The demonstration of the presence of these molecules in vivo could
shed new light on the role that Abs could exert, through their
proteolytic fragments, in the antifungal homeostasis. The fungi-
cidal activity of Fc-peptides and their asds allow to hypothesize
that Abs may represent a source of new molecules that could serve
as prototype drugs exploitable against fungal pathogens.
Figure 5. Cytotoxic effects of N10K on Candida albicans. Yeast
cells were incubated with (panels B, C, D, E, F, and G) or without (panel
A) N10K. Original magnification 120006.
doi:10.1371/journal.pone.0034105.g005
Figure 6. Binding of biotinylated N10K to Candida albicans cells.
A. Cells stained with DAPI; B. Phalloidin-rodamine stained cells. C.
Biotinylated N10K-treated cells stained with streptavidin-fluorescein
isothiocyanate. Fluorescence is seen at the cells’ periphery, mainly at
the cell wall. D. Merge produced by the superposition of the red and
green fluorescence outputs of the same cells. The peptide ligand does
not colocalize with F-actin.
doi:10.1371/journal.pone.0034105.g006
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